Author:
Karanika S,Karantanos T,Li L,Corn P G,Thompson T C
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference106 articles.
1. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 2013; 368: 138–148.
2. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983–992.
3. Beer TM, Armstrong AJ, Sternberg CN, Higano CS, Iversen P, Loriot Y et al. Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): results of phase 3 PREVAIL study. Presented at 2014 Genitourinary Cancers Symposium; 30 January– 1 February 2014; San Francisco, CA, USA.
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sterberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187–1197.
5. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997; 337: 295–300.
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献